Listed on the Toronto Stock Exchange (TSX: AKL)

Akela Pharma (formerly Lab International) is an integrated drug development company focused on developing therapies for the growing multi-billion dollar inhalation and pain markets.  Its lead product, for the treatment of breakthrough cancer pain, is a fast-acting Fentanyl formulation delivered using the Company’s TAIFUN® dry powder inhaler platform. Its pipeline also includes therapeutics for asthma, COPD, and growth hormone deficiencies.